• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cybin Inc. Common Shares (NY: CYBN )

    9.610 +0.290 (+3.11%)
    Official Closing Price Updated: 8:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 393,947
    Open 9.280
    Bid (Size) 9.650 (10)
    Ask (Size) 9.810 (1)
    Prev. Close 9.320
    Today's Range 9.110 - 9.670
    52wk Range 6.500 - 19.85
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Promising Advances in Depression and Anxiety Treatment at ACNP Annual Meeting
    Via Investor Brand Network
    Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
    From Cybin Inc.
    Via Business Wire

    Performance

    YTD
    -36.78%
    -36.78%
    1 Month
    -5.41%
    -5.41%
    3 Month
    -0.21%
    -0.21%
    6 Month
    -4.21%
    -4.21%
    1 Year
    -38.32%
    -38.32%

    More News

    Read More
    PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Water Tower Research Fireside Chat
    Via Investor Brand Network
    Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
    From Cybin Inc.
    Via Business Wire
    Is Your Mind Ready to Consider Investing in Psychedelics Stocks?
    Via The Motley Fool
    InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Sustained 12-Month Efficacy for CYB003 in Treating Major Depressive Disorder
    Via Investor Brand Network
    Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
    From Cybin Inc.
    Via Business Wire
    PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present Key 12-Month Data and Phase 3 Program Insights for CYB003 in Upcoming Webcast
    Via Investor Brand Network
    Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
    From Cybin Inc.
    Via Business Wire
    Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
    Via Benzinga
    Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
    From Cybin Inc.
    Via Business Wire
    InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Begins Phase 3 Trials of CYB003 for Depression, Building on Promising Phase 2 Results
    Via Investor Brand Network
    InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present Advancements in Mental Health Treatment at Milken Institute Summit
    Via Investor Brand Network
    Cybin to Participate at the 2024 Milken Institute Future of Health Summit
    From Cybin Inc.
    Via Business Wire
    BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Granted Patent for Lead Candidates in CYB005 Program
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
    From Cybin Inc.
    Via Business Wire
    EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in Upcoming Water Tower Research Fireside Chat
    Via Investor Brand Network
    Exposures Product Safety
    Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
    From Cybin Inc.
    Via Business Wire
    PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Strengthens Its Clinical Development Team
    Via Investor Brand Network
    Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
    From Cybin Inc.
    Via Business Wire
    InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Chief Medical Officer to Participate in a Panel Discussion at Upcoming Summit
    Via Investor Brand Network
    Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
    From Cybin Inc.
    Via Business Wire
    PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports on Status of Key Clinical Milestones
    Via Investor Brand Network
    Cybin Provides Corporate Update on Upcoming Clinical Milestones
    From Cybin Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.